Overview
- The Supreme Court issued a unanimous 9-0 decision on June 4, 2026, reversing the Federal Circuit and finding that Hikma’s skinny-label generic did not plausibly induce infringement of Amarin’s Vascepa patents.
- Justice Ketanji Brown Jackson wrote that inducement requires affirmative, purposeful acts to encourage infringement and that mere omissions, standard labeling that tracks the brand, or routine marketing are insufficient to meet that test.
- The case returns to lower courts for further proceedings, with Amarin able to seek leave to amend its complaint but now required to allege specific, clear actions by Hikma intended to drive the patented cardiovascular use.
- Hikma praised the ruling as ensuring continued access to lower-cost generics, and industry observers say the decision reduces legal risk for future skinny-label launches that let generics sell for non-patented uses.
- The ruling preserves a long-used FDA pathway called a section viii or skinny label that has enabled earlier generic entry and large cost savings for payers and patients, while leaving brand holders a narrower route to challenge conduct that plainly seeks to push patented uses.